{
    "organizations": [],
    "uuid": "e5cf702e4bdc4a78fff84bd408ff56b7f9be4d35",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-actinium-announces-submission-of-i/brief-actinium-announces-submission-of-ind-for-actimab-a-in-combination-with-clag-m-for-patients-with-relapsed-or-refractory-aml-idUSFWN1Q21GX",
    "ord_in_thread": 0,
    "title": "BRIEF-Actinium Announces Submission Of IND For Actimab-A In Combination With Clag-M For Patients With Relapsed Or Refractory AML",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Actinium Pharmaceuticals Inc:\n* ACTINIUM ANNOUNCES SUBMISSION OF IND FOR ACTIMAB-A IN COMBINATION WITH CLAG-M FOR PATIENTS WITH RELAPSED OR REFRACTORY AML Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T05:44:00.000+02:00",
    "crawled": "2018-02-13T15:31:43.034+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "actinium",
        "pharmaceutical",
        "inc",
        "actinium",
        "announces",
        "submission",
        "ind",
        "combination",
        "patient",
        "relapsed",
        "refractory",
        "aml",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}